Teva Pharmaceutical Industries Ltd.

Legal Proceedings Report • Oct 24, 2019

Teva Settled Track 1 Opioid Cases and Reaches Agreement on Framework to Settle Remaining Litigation on October 21 2019 false

��� ������ ��������� ��"�	2 380
TEVA- PHARMACEUTICAL INDUSTRIES LTD
Corporation no: 520013954	11947
- - -

	Israel Securities Authority			Tel Aviv Stock Exchange		C002 ( Public )		Reported via MAGNA:	24/10/2019
	www.isa.gov.il			www.tase.co.il				Reference:	2019-02-104722	Time of broadcast: 00:21 00:16:23

---

Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

	The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report onTeva Settled Track 1 Opioid Cases and Reaches Agreement on Framework to Settle Remaining Litigation on October 21 2019

Teva_Settled_Track_1_Opioid_Cases_and_Reaches_Agreement_on_Framework_to_Settle_Remaining_Litigation.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
- - -
Stock Exchange/Market: NYSE	Date of revision of form structure: 06/08/2019
Address: P.O.B 3190 , Petach Tikva 49131   , Tel: 03-9267267 , 03-9267652 Fax: 03-9267519
E-mail address: tomer.amitai@teva.co.il
Previous names of reporting entity:
Name of the Signatory: MCCLELLAN MICHAEL Position of Signatory in the reporting corporation: Chief Financial Officer Name of Employer Company:
Address: Basel 5 , Petach-Tikva 4951033 Telephone: 03-9148213 Facsimile: 03-9148671 E-mail: Michael.McClellan@tevapharm.com 1